基因組學合作與授權協議（2018-2025）

"基因組學合作與許可協議" 報告全面深入分析了全球領先的生物製藥公司簽署的基因組學相關協議，並提供前所未有的資訊取得管道。

這份經過全面修訂和更新的報告詳細介紹了2018年至2025年間的基因組學相關協議。

本報告深入分析了企業簽署基因組學相關協議的原因和方式。這些協議通常包含多個組成部分，從合作研發開始，最終實現成果的商業化。

本報告涵蓋合作、開發、研究和授權等內容。

本報告列出了自2018年以來宣布的639項基因組學相關交易，並提供了可用的財務條款以及相關方披露的實際基因組學合作在線記錄的鏈接。此外，在條件允許的情況下，記錄還包括公司及其合作夥伴向美國證券交易委員會提交的合約文件。

本報告的引言概述了基因組學相關交易。

第一章概述了本報告。

第二章概述了自 2018 年以來基因組學相關交易的趨勢。

第三章概述了自 2018 年以來主要的基因組學相關交易，並依交易額列出。

第四章提供了基因組學相關交易中最活躍的 25 家公司的完整列表，並附有簡要概述，隨後提供了基因組學相關交易和公開合約文件的完整列表。

第五章對自 2018 年 1 月以來已完成或已宣布的、且有公開合約文件的基因組學相關交易進行了全面深入的審查。

第六章對自2018年1月以來已完成或宣布的基因組學合作交易進行了全面深入的回顧。本章以具體的基因組學技術類型進行組織。

報告還包含大量表格和圖表，展示了自2018年以來基因組學相關交易的趨勢和活動。

此外，我們還提供了一個全面的交易目錄，依公司名稱（A-Z）、交易類型和治療靶點進行分類。每個交易標題都透過網路連結指向交易記錄的線上版本，並在可用的情況下指向協議文件，以便根據需要輕鬆存取每個文件。

主要優勢

基因體學合作與授權協議報告為讀者提供以下主要優勢：

• 了解 2018 年及以後的交易趨勢
• 查看基因體學相關的合作與授權協議
• 基準分析 - 確定交易市場價值
• 財務條款 - 首付款、里程碑付款、特許權使用費
• 依公司（A-Z）、協議類型和治療領域分類的合約目錄
• 以交易價值排名的熱門交易
• 最活躍的交易撮合者
• 確定每筆交易的資產詳情和合約條款
• 存取合約文件 - 深入了解交易結構
• 盡職調查 - 評估擬議交易條款對合作公司的適用性
• 節省數百小時的研究時間

範圍

• "基因組學合作與許可協議" 報告旨在幫助讀者深入了解全球生物製藥公司的基因組學趨勢和合約結構。

基因體學合作與授權協議包括：

• 生物製藥產業的基因組學交易趨勢
• 製藥和生物技術公司基因組學交易記錄目錄
• 依價值排名的主要基因組學交易
• 最活躍的基因組學授權協議公司
• "基因組學合作與許可協議" 提供對可用協議記錄的全面訪問，包括合約文件（如有）。

分析合約有助於對以下內容進行盡職調查：

• 合約具體授予或選擇哪些權利？
• 合約實際授予合作公司哪些權利？
• 授予哪些獨家權利？
• 交易的付款結構是什麼？
• 銷售和付款如何審計？
• 合約期限是多久？
• 合約的關鍵條款是如何定義的？
• 知識產權（IPR）如何處理與歸屬？
• 誰負責商業化？
• 誰負責開發、供應和生產？
• 如何管理保密性和資訊揭露？
• 如何解決爭議？
• 在什麼情況下可以終止協議？
• 如果所有權發生變更，會發生什麼事？
• 如何約定轉讓許可和分包條款？
• 貴公司要求哪些標準條款？
• 哪些標準條款會因交易對手和交易類型而異？
• 貴公司必須在哪個司法管轄區管轄其合約？

目錄

摘要整理

第一章：引言

第二章：基因體學交易趨勢

• 引言
• 歷年基因體學交易
• 最活躍的基因組學交易商
• 依交易類型劃分的基因組學交易
• 依治療領域劃分的基因體學交易
• 依行業劃分的基因組學相關交易
• 基因體學交易條款
  • 基因體學交易的關鍵價值因素
  • 基因組學交易的預付款
  • 基因組學交易的里程碑付款
  • 基因組學特許權使用費率

第三章：基因體學的關鍵要素交易

• 引言
• 依價值排名的基因組學相關頂級交易

第四章 - 最活躍的基因組學經銷商

• 引言
• 最活躍的基因組學經銷商
• 最活躍的基因組學經銷商公司簡介

第五章：基因組學合約交易目錄

• 引言
• 基因組學合約交易目錄

第六章：依技術類型劃分的基因體學交易

• 交易目錄
• 依公司劃分的基因組學交易目錄 (AZ)
• 依交易類型劃分的基因組學交易目錄
• 依治療領域劃分的基因體學交易目錄
• 交易類型定義
• 關於研究公司
• 當前合作夥伴
• 當前協議
• 近期合作夥伴報告標題

Genomic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the genomic deals entered into by the world's leading biopharma companies.

Fully revised and updated, the report provides details of genomic deals from 2018 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter genomic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 639 genomic deals announced since 2018 including financial terms where available including links to online deal records of actual genomic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of genomic dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in genomic dealmaking since 2018.

Chapter 3 provides an overview of the leading genomic deals since 2018. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in genomic dealmaking with a brief summary followed by a comprehensive listing of genomic deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of genomic deals signed and announced since Jan 2018, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of genomic partnering deals signed and announced since Jan 2018. The chapter is organized by specific genomic technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in genomic deal making since 2018.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Genomic Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2018
• Browse genomic collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Genomic Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of genomic trends and structure of deals entered into by leading biopharma companies worldwide.

Genomic Collaboration and Licensing Deals includes:

• Trends in genomic dealmaking in the biopharma industry
• Directory of genomic deal records covering pharmaceutical and biotechnology
• The leading genomic deals by value
• Most active genomic licensing dealmakers
• Genomic Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in genomic dealmaking

• 2.1. Introduction
• 2.2. Genomic deals over the years
• 2.3. Most active genomic dealmakers
• 2.4. Genomic deals by deal type
• 2.5. Genomic deals by therapy area
• 2.6. Genomic deals by industry sector
• 2.7. Deal terms for genomic deals
  • 2.7.1 Genomic deals headline values
  • 2.7.2 Genomic deal upfront payments
  • 2.7.3 Genomic deal milestone payments
  • 2.7.4 Genomic royalty rates

Chapter 3 - Leading genomic deals

• 3.1. Introduction
• 3.2. Top genomic deals by value

Chapter 4 - Most active genomic dealmakers

• 4.1. Introduction
• 4.2. Most active genomic dealmakers
• 4.3. Most active genomic deals company profiles

Chapter 5 - Genomic contracts dealmaking directory

• 5.1. Introduction
• 5.2. Genomic contracts dealmaking directory

Chapter 6 - Genomic dealmaking by technology type

• Deal directory
• Deal directory - Genomic deals by company A-Z
• Deal directory - Genomic deals by deal type
• Deal directory - Genomic deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Genomic deals since 2018
• Figure 2: Active genomic dealmaking activity - 2018 - 2025
• Figure 3: Genomic deals by deal type since 2018
• Figure 4: Genomic deals by therapy area since 2018
• Figure 5: Genomic deals by industry sector since 2018
• Figure 6: Genomic deals with a headline value
• Figure 7: Genomic deals with an upfront value
• Figure 8: Genomic deals with a milestone value
• Figure 9: Genomic deals with a royalty rate value
• Figure 10: Top genomic deals by value since 2018
• Figure 11: Most active genomic dealmakers 2018 - 2025
• Figure 12: Genomic deals by technology type since 2018